AS1402, a humanized immunoglobin monoclonal antibody binding to the MUC1-N tandem, showed antibody-dependent cytotoxicity against MUC-1-positive breast cancer cells in a phase I trial [18]. This evidence concerns the gene MUC1 and breast carcinoma.